NovoCure Ltd 8K

Novocure reported strong second quarter 2026 financial and operational results, raised full-year guidance, and announced CE Mark approval in Europe for Optune Pax in locally advanced pancreatic cancer.

On July 23, 2026, Novocure Limited reported its financial and operational results for the quarter ended June 30, 2026, highlighting record quarterly net revenues of $183.6 million (up 16% year-over-year) driven by 18% global active patient growth, improved gross margin to 78% helped by a one-time tariff refund, a narrowed net loss of $15.7 million, and positive Adjusted EBITDA of $10.8 million. The company provided updated full-year 2026 guidance, raising expected total net revenue to $710–$725 million and Adjusted EBITDA to a range of $0–$15 million, underpinned by growing adoption of its TTFields therapies, including Optune Gio, Optune Lua and Optune Pax. Operationally, total active patients on TTFields therapy reached 5,128 worldwide, with 285 active Optune Pax patients in the U.S., and the company reported that Optune Pax received a CE Mark in June 2026 for the treatment of adult patients with locally advanced pancreatic cancer in Europe, with Germany as the first launch market. Novocure also outlined key anticipated milestones, including a Q4 2026 FDA decision on TTFields for brain metastases from non-small cell lung cancer and completion of enrollment in the Phase 3 KEYNOTE D58 trial in newly diagnosed glioblastoma.

Filing Facts

CIK

1645113

Ticker

-

Form

8K

Source Type

sec

Accession

0001645113-26-000063

Alert Tier

7